Kimberly-Clark Announces Third Quarter 2013 Results
Executive Summary
- Third quarter 2013 net sales of
$5.3 billion were even with the year-ago period. Organic sales rose 5 percent, including a 10 percent increase inK-C International . Organic sales exclude the impact of changes in foreign currency exchange rates and lost sales as a result of European strategic changes and pulp and tissue restructuring actions. - Diluted net income per share for the third quarter of 2013 was
$1.42 versus$1.30 in 2012. - Third quarter adjusted earnings per share were
$1.44 in 2013 compared to$1.34 in the prior year. The improvement was driven by organic sales growth, cost savings, a lower effective tax rate and a lower share count, partially offset by input cost inflation and unfavorable foreign currency rates. Third quarter 2013 adjusted earnings per share exclude restructuring costs for European strategic changes. Adjusted earnings per share in the third quarter of 2012 exclude costs for pulp and tissue restructuring actions. - Full-year 2013 adjusted earnings per share are anticipated to be
$5.65 to$5.75 compared to the company's previous guidance range of$5.60 to$5.75 . Estimated 2013 adjusted earnings per share exclude restructuring costs for European strategic changes and a balance sheet remeasurement charge due to theFebruary 2013 devaluation of the Venezuelan bolivar.
Chairman and Chief Executive Officer
Third Quarter 2013 Operating Results
Sales of
Operating profit was
The third quarter effective tax rate was 30.3 percent in 2013 compared to 31.1 percent in 2012. The third quarter adjusted effective tax rate, which does not include the effect of the previously mentioned item excluded from adjusted earnings per share calculations, was 30.2 percent in 2013, in line with the anticipated full-year rate of 30 to 32 percent. The third quarter adjusted effective tax rate was 31.8 percent in 2012.
Cash provided by operations in the third quarter of 2013 was
Capital spending for the third quarter was $203 million in 2013 and $277 million in 2012. Full-year 2013 spending is expected to be toward the low end of the previously communicated target range of
Third Quarter 2013 Business Segment Results
Personal Care Segment
Third quarter sales of
Sales in
Sales in
Sales in
Consumer Tissue Segment
Third quarter sales of
Sales in
Sales in
Sales in
K-C Professional (KCP) Segment
Third quarter sales of
Sales in
Sales in
Sales in
Health Care Segment
Third quarter sales of
Medical device volumes were up high-single digits, with strong growth in pain management products and solid increases in airway management and digestive health offerings. Surgical and infection prevention volumes were up slightly, as higher sales of surgical products and face masks were mostly offset by declines in exam gloves.
Year-To-Date Results
For the first nine months of 2013, sales of
Year-to-date operating profit of
Through nine months, diluted net income per share was
Adjusted operating profit and adjusted earnings per share in 2013 exclude restructuring costs for European strategic changes and a balance sheet remeasurement charge due to the
Western and Central European Businesses Strategic Changes — Update
In
Restructuring costs for these actions will be incurred through 2014 and are expected to be toward the high end of the previously communicated range of
2013 Outlook — Update
Adjusted earnings per share are expected to be
Non-GAAP Financial Measures
This press release and the accompanying tables include the following financial measures that have not been calculated in accordance with accounting principles generally accepted in the U.S., or GAAP, and are therefore referred to as non-GAAP financial measures:
- Adjusted earnings and earnings per share
- Adjusted gross and operating profit
- Adjusted effective tax rate
These non-GAAP financial measures exclude the following items:
- Western and
Central Europe strategic changes and related restructuring charges. InOctober 2012 , the company initiated strategic changes and a related restructuring in its Western and Central European businesses in order to improve underlying profitability and focus its resources on its strongest market positions and growth opportunities. The restructuring is expected to be completed byDecember 31 , 2014. Restructuring charges related to these strategic changes were excluded from the calculation of the company's earnings and earnings per share, calculated in accordance with GAAP, for the full year 2012, earnings and earnings per share, gross and operating profit and effective tax rate, calculated in accordance with GAAP, for the three and nine months endedSeptember 30, 2013 , and the estimated earnings per share and estimated effective tax rate, calculated in accordance with GAAP, for the full year 2013. - Balance sheet remeasurement charge due to devaluation of Venezuelan bolivar. In the first quarter of 2013, the company recorded a charge for the remeasurement of the local currency-denominated balance sheet due to the
February 2013 devaluation of the Venezuelan bolivar. This charge was excluded from the calculation of the company's earnings and earnings per share, operating profit and effective tax rate, calculated in accordance with GAAP, for the nine months endedSeptember 30, 2013 , and the estimated earnings per share and estimated effective tax rate, calculated in accordance with GAAP, for the full year 2013. - Pulp and tissue restructuring charges. In 2011 and 2012, the company executed pulp and tissue restructuring actions to exit its remaining integrated pulp manufacturing operations and improve the underlying profitability and return on invested capital of its consumer tissue and K-C Professional businesses. The restructuring actions were substantially completed by December 31, 2012. Pulp and tissue restructuring charges were excluded from the calculation of the company's earnings and earnings per share, gross and operating profit and the effective tax rate, calculated in accordance with GAAP, for the three and nine months ended
September 30, 2012 , and earnings and earnings per share, calculated in accordance with GAAP, for the full year 2012.
In accordance with the
In addition, this press release includes information regarding organic sales, which exclude the impact of changes in foreign currency rates and lost sales in conjunction with European strategic changes and pulp and tissue restructuring actions.
The company provides these non-GAAP financial measures as supplemental information to our GAAP financial measures. Management and the company's Board of Directors use adjusted earnings, adjusted earnings per share and adjusted gross and operating profit to (a) evaluate the company's historical and prospective financial performance and its performance relative to its competitors, (b) allocate resources and (c) measure the operational performance of the company's business units and their managers. Management also believes that the use of adjusted effective tax rate provides improved insight into the tax effects of our ongoing business operations.
Additionally, the
In addition,
These non-GAAP financial measures are not meant to be considered in isolation or as a substitute for the comparable GAAP measures. There are limitations to these non-GAAP financial measures because they are not prepared in accordance with GAAP and may not be comparable to similarly titled measures of other companies due to potential differences in methods of calculation and items being excluded. The company compensates for these limitations by using these non-GAAP financial measures as a supplement to the GAAP measures and by providing reconciliations of the non-GAAP and comparable GAAP financial measures. The non-GAAP financial measures should be read only in conjunction with the company's consolidated financial statements prepared in accordance with GAAP.
Conference Call
A conference call to discuss this news release and other matters of interest to investors and analysts will be held at
About
Copies of
Certain matters contained in this news release concerning the business outlook, including anticipated financial and operating results, the anticipated costs, scope, timing and financial and other effects of the Western and
|
| |||||||||
|
CONSOLIDATED INCOME STATEMENT | |||||||||
|
(Millions, except per share amounts) | |||||||||
|
Three Months Ended |
|||||||||
|
2013 |
2012 |
Change | |||||||
|
Net Sales |
$ |
5,262 |
$ |
5,246 |
+0.3% | ||||
|
Cost of products sold |
3,457 |
3,480 |
-0.7% | ||||||
|
Gross Profit |
1,805 |
1,766 |
+2.2% | ||||||
|
Marketing, research and general expenses |
990 |
988 |
+0.2% | ||||||
|
Other (income) and expense, net |
8 |
(5) |
N.M. | ||||||
|
Operating Profit |
807 |
783 |
+3.1% | ||||||
|
Interest income |
6 |
4 |
+50.0% | ||||||
|
Interest expense |
(73) |
(70) |
+4.3% | ||||||
|
Income Before Income Taxes and Equity Interests |
740 |
717 |
+3.2% | ||||||
|
Provision for income taxes |
(224) |
(223) |
+0.4% | ||||||
|
Income Before Equity Interests |
516 |
494 |
+4.5% | ||||||
|
Share of net income of equity companies |
49 |
43 |
+14.0% | ||||||
|
Net Income |
565 |
537 |
+5.2% | ||||||
|
Net income attributable to noncontrolling interests |
(19) |
(20) |
-5.0% | ||||||
|
Net Income Attributable to |
$ |
546 |
$ |
517 |
+5.6% | ||||
|
Per Share Basis |
|||||||||
|
Net Income Attributable to |
|||||||||
|
Basic |
$ |
1.43 |
$ |
1.31 |
+9.2% | ||||
|
Diluted |
$ |
1.42 |
$ |
1.30 |
+9.2% | ||||
|
Cash Dividends Declared |
$ |
0.81 |
$ |
0.74 |
+9.5% | ||||
|
Common Shares Outstanding |
September 30 |
||||||||
|
2013 |
2012 |
||||||||
|
Outstanding shares as of |
382.1 |
392.3 |
|||||||
|
Average diluted shares for three months ended |
385.8 |
396.7 |
|||||||
|
N.M. — Not meaningful | |||||||||
|
Unaudited | |||||||||
|
| |||||||||
|
CONSOLIDATED INCOME STATEMENT | |||||||||
|
(Millions, except per share amounts) | |||||||||
|
Nine Months Ended |
|||||||||
|
2013 |
2012 |
Change | |||||||
|
Net Sales |
$ |
15,847 |
$ |
15,756 |
+0.6% | ||||
|
Cost of products sold |
10,420 |
10,531 |
-1.1% | ||||||
|
Gross Profit |
5,427 |
5,225 |
+3.9% | ||||||
|
Marketing, research and general expenses |
3,029 |
3,003 |
+0.9% | ||||||
|
Other (income) and expense, net |
12 |
(15) |
N.M. | ||||||
|
Operating Profit |
2,386 |
2,237 |
+6.7% | ||||||
|
Interest income |
16 |
13 |
+23.1% | ||||||
|
Interest expense |
(211) |
(212) |
-0.5% | ||||||
|
Income Before Income Taxes and Equity Interests |
2,191 |
2,038 |
+7.5% | ||||||
|
Provision for income taxes |
(685) |
(621) |
+10.3% | ||||||
|
Income Before Equity Interests |
1,506 |
1,417 |
+6.3% | ||||||
|
Share of net income of equity companies |
157 |
125 |
+25.6% | ||||||
|
Net Income |
1,663 |
1,542 |
+7.8% | ||||||
|
Net income attributable to noncontrolling interests |
(60) |
(59) |
+1.7% | ||||||
|
Net Income Attributable to |
$ |
1,603 |
$ |
1,483 |
+8.1% | ||||
|
Per Share Basis |
|||||||||
|
Net Income Attributable to |
|||||||||
|
Basic |
$ |
4.16 |
$ |
3.77 |
+10.3% | ||||
|
Diluted |
$ |
4.13 |
$ |
3.73 |
+10.7% | ||||
|
Cash Dividends Declared |
$ |
2.43 |
$ |
2.22 |
+9.5% | ||||
|
Common Shares Outstanding |
September 30 |
||||||||
|
2013 |
2012 |
||||||||
|
Average diluted shares for nine months ended |
388.0 |
397.1 |
|||||||
|
N.M. — Not meaningful | |||||||||
|
Unaudited | |||||||||
|
| ||||||||||||
|
NON-GAAP RECONCILIATIONS | ||||||||||||
|
(Millions, except per share amounts) | ||||||||||||
|
Three Months Ended | ||||||||||||
|
As Reported |
Charges for European Strategic Changes |
As Adjusted Non-GAAP | ||||||||||
|
Cost of products sold |
$ |
3,457 |
$ |
6 |
$ |
3,451 |
||||||
|
Gross profit |
1,805 |
(6) |
1,811 |
|||||||||
|
Marketing, research and general expenses |
990 |
5 |
985 |
|||||||||
|
Other (income) and expense, net |
8 |
3 |
5 |
|||||||||
|
Operating profit |
807 |
(14) |
821 |
|||||||||
|
Income before income taxes and equity interests |
740 |
(14) |
754 |
|||||||||
|
Provision for income taxes |
(224) |
4 |
(228) |
|||||||||
|
Effective tax rate |
30.3 |
% |
— |
30.2 |
% | |||||||
|
Income before equity interests |
516 |
(10) |
526 |
|||||||||
|
Net income |
565 |
(10) |
575 |
|||||||||
|
Net income attributable to Kimberly-Clark Corporation |
546 |
(10) |
556 |
|||||||||
|
Diluted earnings per share(a) |
1.42 |
(0.03) |
1.44 |
|||||||||
|
Three Months Ended | ||||||||||||
|
As Reported |
Charges for Pulp and Tissue Restructuring |
As Adjusted Non-GAAP | ||||||||||
|
Cost of products sold |
$ |
3,480 |
$ |
30 |
$ |
3,450 |
||||||
|
Gross profit |
1,766 |
(30) |
1,796 |
|||||||||
|
Marketing, research and general expenses |
988 |
1 |
987 |
|||||||||
|
Operating profit |
783 |
(31) |
814 |
|||||||||
|
Income before income taxes and equity interests |
717 |
(31) |
748 |
|||||||||
|
Provision for income taxes |
(223) |
15 |
(238) |
|||||||||
|
Effective tax rate |
31.1 |
% |
— |
31.8 |
% | |||||||
|
Income before equity interests |
494 |
(16) |
510 |
|||||||||
|
Net income |
537 |
(16) |
553 |
|||||||||
|
Net income attributable to |
517 |
(16) |
533 |
|||||||||
|
Diluted earnings per share |
1.30 |
(0.04) |
1.34 |
|||||||||
|
(a) "As Adjusted Non-GAAP" does not equal "As Reported" plus "Charges" as a result of rounding. | ||||||||||||
|
Unaudited | ||||||||||||
|
| ||||||||||||||||
|
NON-GAAP RECONCILIATIONS | ||||||||||||||||
|
(Millions, except per share amounts) | ||||||||||||||||
|
Nine Months Ended | ||||||||||||||||
|
As Reported |
Charges for European Strategic Changes |
Charge for Venezuelan Bolivar Devaluation |
As Adjusted Non-GAAP | |||||||||||||
|
Cost of products sold |
$ |
10,420 |
$ |
44 |
$ |
— |
$ |
10,376 |
||||||||
|
Gross profit |
5,427 |
(44) |
— |
5,471 |
||||||||||||
|
Marketing, research and general expenses |
3,029 |
20 |
— |
3,009 |
||||||||||||
|
Other (income) and expense, net |
12 |
3 |
36 |
(27) |
||||||||||||
|
Operating profit |
2,386 |
(67) |
(36) |
2,489 |
||||||||||||
|
Income before income taxes and equity interests |
2,191 |
(67) |
(36) |
2,294 |
||||||||||||
|
Provision for income taxes |
(685) |
15 |
10 |
(710) |
||||||||||||
|
Effective tax rate |
31.3 |
% |
— |
— |
31.0 |
% | ||||||||||
|
Income before equity interests |
1,506 |
(52) |
(26) |
1,584 |
||||||||||||
|
Net income |
1,663 |
(52) |
(26) |
1,741 |
||||||||||||
|
Net income attributable to Kimberly-Clark Corporation |
1,603 |
(52) |
(26) |
1,681 |
||||||||||||
|
Diluted earnings per share |
4.13 |
(0.13) |
(0.07) |
4.33 |
||||||||||||
|
Nine Months Ended | ||||||||||||
|
As Reported |
Charges for Pulp and Tissue Restructuring |
As Adjusted Non-GAAP | ||||||||||
|
Cost of products sold |
$ |
10,531 |
$ |
83 |
$ |
10,448 |
||||||
|
Gross profit |
5,225 |
(83) |
5,308 |
|||||||||
|
Marketing, research and general expenses |
3,003 |
2 |
3,001 |
|||||||||
|
Operating profit |
2,237 |
(85) |
2,322 |
|||||||||
|
Income before income taxes and equity interests |
2,038 |
(85) |
2,123 |
|||||||||
|
Provision for income taxes |
(621) |
29 |
(650) |
|||||||||
|
Effective tax rate |
30.5 |
% |
— |
30.6 |
% | |||||||
|
Income before equity interests |
1,417 |
(56) |
1,473 |
|||||||||
|
Net income |
1,542 |
(56) |
1,598 |
|||||||||
|
Net income attributable to Kimberly-Clark Corporation |
1,483 |
(56) |
1,539 |
|||||||||
|
Diluted earnings per share(a) |
3.73 |
(0.14) |
3.88 |
|||||||||
|
(a) "As Adjusted Non-GAAP" does not equal "As Reported" plus "Charges" as a result of rounding. | ||||||||||||
|
Twelve Months Ended | ||||||||||||||||
|
As Reported |
Charges for Pulp and Tissue Restructuring |
Charges for European Strategic Changes |
As Adjusted Non-GAAP | |||||||||||||
|
Net income attributable to |
$ |
1,750 |
$ |
(86) |
$ |
(242) |
$ |
2,078 |
||||||||
|
Diluted earnings per share |
4.42 |
(0.22) |
(0.61) |
5.25 |
||||||||||||
|
Unaudited |
||||||||||||||||
|
| |||||||
|
CONSOLIDATED BALANCE SHEET | |||||||
|
(Millions) | |||||||
|
September 30, |
December 31, | ||||||
|
ASSETS |
|||||||
|
Current Assets |
|||||||
|
Cash and cash equivalents |
$ |
1,179 |
$ |
1,106 |
|||
|
Accounts receivable, net |
2,502 |
2,642 |
|||||
|
Note receivable |
396 |
— |
|||||
|
Inventories |
2,245 |
2,348 |
|||||
|
Other current assets |
572 |
493 |
|||||
|
Total Current Assets |
6,894 |
6,589 |
|||||
|
Property, Plant and Equipment, Net |
7,871 |
8,095 |
|||||
|
Investments in Equity Companies |
429 |
355 |
|||||
|
Goodwill |
3,223 |
3,337 |
|||||
|
Other Intangible Assets |
257 |
246 |
|||||
|
Long-Term Note Receivable |
— |
395 |
|||||
|
Other Assets |
690 |
856 |
|||||
|
TOTAL ASSETS |
$ |
19,364 |
$ |
19,873 |
|||
|
LIABILITIES AND STOCKHOLDERS' EQUITY |
|||||||
|
Current Liabilities |
|||||||
|
Debt payable within one year |
$ |
1,087 |
$ |
1,115 |
|||
|
Trade accounts payable |
2,360 |
2,443 |
|||||
|
Accrued expenses |
2,023 |
2,244 |
|||||
|
Dividends payable |
310 |
289 |
|||||
|
Total Current Liabilities |
5,780 |
6,091 |
|||||
|
Long-Term Debt |
5,388 |
5,070 |
|||||
|
Noncurrent Employee Benefits |
1,725 |
1,992 |
|||||
|
Other Liabilities |
946 |
884 |
|||||
|
|
549 |
549 |
|||||
|
Stockholders' Equity |
|||||||
|
|
4,667 |
4,985 |
|||||
|
Noncontrolling interests |
309 |
302 |
|||||
|
Total Stockholders' Equity |
4,976 |
5,287 |
|||||
|
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY |
$ |
19,364 |
$ |
19,873 |
|||
|
| |||||||
|
| |||||||||||||||
|
CONSOLIDATED CASH FLOW STATEMENT | |||||||||||||||
|
(Millions) | |||||||||||||||
|
Three Months Ended |
Nine Months Ended | ||||||||||||||
|
2013 |
2012 |
2013 |
2012 | ||||||||||||
|
Operating Activities |
|||||||||||||||
|
Net income |
$ |
565 |
$ |
537 |
$ |
1,663 |
$ |
1,542 |
|||||||
|
Depreciation and amortization |
208 |
210 |
641 |
642 |
|||||||||||
|
Asset impairments |
42 |
— |
42 |
— |
|||||||||||
|
Stock-based compensation |
21 |
14 |
73 |
57 |
|||||||||||
|
Deferred income taxes |
58 |
146 |
128 |
320 |
|||||||||||
|
Net (gains) losses on asset dispositions |
(5) |
(2) |
— |
15 |
|||||||||||
|
Equity companies' earnings in excess of dividends paid |
(9) |
(8) |
(75) |
(53) |
|||||||||||
|
(Increase) decrease in operating working capital |
29 |
(26) |
(259) |
(335) |
|||||||||||
|
Postretirement benefits |
13 |
(33) |
(135) |
(11) |
|||||||||||
|
Other |
(10) |
6 |
17 |
(8) |
|||||||||||
|
Cash Provided by Operations |
912 |
844 |
2,095 |
2,169 |
|||||||||||
|
Investing Activities |
|||||||||||||||
|
Capital spending |
(203) |
(277) |
(697) |
(763) |
|||||||||||
|
Acquisitions of businesses |
(30) |
— |
(32) |
(5) |
|||||||||||
|
Proceeds from dispositions of property |
27 |
— |
113 |
6 |
|||||||||||
|
Proceeds from sales of investments |
6 |
7 |
16 |
14 |
|||||||||||
|
Investments in time deposits |
(46) |
(24) |
(46) |
(61) |
|||||||||||
|
Maturities of time deposits |
46 |
35 |
66 |
78 |
|||||||||||
|
Other |
1 |
2 |
(10) |
2 |
|||||||||||
|
Cash Used for Investing |
(199) |
(257) |
(590) |
(729) |
|||||||||||
|
Financing Activities |
|||||||||||||||
|
Cash dividends paid |
(311) |
(292) |
(913) |
(859) |
|||||||||||
|
Change in short-term borrowings |
289 |
196 |
22 |
464 |
|||||||||||
|
Debt proceeds |
3 |
6 |
889 |
315 |
|||||||||||
|
Debt repayments |
(502) |
(50) |
(542) |
(471) |
|||||||||||
|
Cash paid on redeemable preferred securities of subsidiary |
(7) |
(7) |
(21) |
(21) |
|||||||||||
|
Proceeds from exercise of stock options |
18 |
99 |
164 |
523 |
|||||||||||
|
Acquisitions of common stock for the treasury |
(165) |
(311) |
(959) |
(962) |
|||||||||||
|
Other |
(1) |
11 |
7 |
25 |
|||||||||||
|
Cash Used for Financing |
(676) |
(348) |
(1,353) |
(986) |
|||||||||||
|
Effect of Exchange Rate Changes on Cash and Cash Equivalents |
(18) |
16 |
(79) |
31 |
|||||||||||
|
Increase (Decrease) in Cash and Cash Equivalents |
19 |
255 |
73 |
485 |
|||||||||||
|
Cash and Cash Equivalents - Beginning of Period |
1,160 |
994 |
1,106 |
764 |
|||||||||||
|
Cash and Cash Equivalents - End of Period |
$ |
1,179 |
$ |
1,249 |
$ |
1,179 |
$ |
1,249 |
|||||||
|
Unaudited | |||||||||||||||
|
|
|||||||||||||||||||||
|
SELECTED BUSINESS SEGMENT DATA |
|||||||||||||||||||||
|
(Millions) |
|||||||||||||||||||||
|
Three Months Ended |
Nine Months Ended |
||||||||||||||||||||
|
2013 |
2012 |
Change |
2013 |
2012 |
Change | ||||||||||||||||
|
NET SALES |
|||||||||||||||||||||
|
Personal Care |
$ |
2,383 |
$ |
2,414 |
-1.3% |
$ |
7,170 |
$ |
7,196 |
-0.4% | |||||||||||
|
Consumer Tissue |
1,626 |
1,605 |
+1.3% |
4,969 |
4,852 |
+2.4% | |||||||||||||||
|
K-C Professional |
843 |
822 |
+2.6% |
2,477 |
2,458 |
+0.8% | |||||||||||||||
|
Health Care |
403 |
396 |
+1.8% |
1,201 |
1,212 |
-0.9% | |||||||||||||||
|
Corporate & Other |
7 |
9 |
N.M. |
30 |
38 |
N.M. | |||||||||||||||
|
TOTAL NET SALES |
$ |
5,262 |
$ |
5,246 |
+0.3% |
$ |
15,847 |
$ |
15,756 |
+0.6% | |||||||||||
|
OPERATING PROFIT |
|||||||||||||||||||||
|
Personal Care |
$ |
427 |
$ |
436 |
-2.1% |
$ |
1,300 |
$ |
1,241 |
+4.8% | |||||||||||
|
Consumer Tissue |
233 |
216 |
+7.9% |
713 |
652 |
+9.4% | |||||||||||||||
|
K-C Professional |
155 |
144 |
+7.6% |
459 |
407 |
+12.8% | |||||||||||||||
|
Health Care |
70 |
59 |
+18.6% |
168 |
168 |
— | |||||||||||||||
|
Corporate & Other(a) |
(70) |
(77) |
N.M. |
(242) |
(246) |
N.M. | |||||||||||||||
|
Other (income) and expense, net |
8 |
(5) |
N.M. |
12 |
(15) |
N.M. | |||||||||||||||
|
TOTAL OPERATING PROFIT |
$ |
807 |
$ |
783 |
+3.1% |
$ |
2,386 |
$ |
2,237 |
+6.7% | |||||||||||
|
(a) |
For the three and nine months ended September 30, 2013, Corporate & Other includes charges related to the European strategic changes of |
|
N.M. — Not meaningful | |
|
Unaudited | |
|
| |||||||||||||||||||||
|
SELECTED BUSINESS SEGMENT DATA | |||||||||||||||||||||
|
PERCENTAGE CHANGE IN NET SALES VERSUS PRIOR YEAR | |||||||||||||||||||||
|
Three Months Ended |
|||||||||||||||||||||
|
Total |
Organic Volume |
Restructuring Impact on Volume(a) |
Total Volume |
Net Price |
Mix/ Other(b) |
Currency | |||||||||||||||
|
Consolidated |
0.3 |
3 |
(2) |
1 |
1 |
— |
(2) |
||||||||||||||
|
Personal Care |
(1.3) |
5 |
(4) |
1 |
— |
1 |
(3) |
||||||||||||||
|
Consumer Tissue |
1.3 |
1 |
(2) |
(1) |
3 |
1 |
(2) |
||||||||||||||
|
K-C Professional |
2.6 |
2 |
(1) |
1 |
2 |
2 |
(2) |
||||||||||||||
|
Health Care |
1.8 |
3 |
— |
3 |
— |
1 |
(2) |
||||||||||||||
|
Nine Months Ended |
|||||||||||||||||||||
|
Total |
Organic Volume |
Restructuring Impact on Volume(a) |
Total Volume |
Net Price |
Mix/ Other(b) |
Currency | |||||||||||||||
|
Consolidated |
0.6 |
3 |
(2) |
1 |
1 |
1 |
(2) |
||||||||||||||
|
Personal Care |
(0.4) |
4 |
(3) |
1 |
1 |
— |
(2) |
||||||||||||||
|
Consumer Tissue |
2.4 |
2 |
(1) |
1 |
2 |
— |
(1) |
||||||||||||||
|
K-C Professional |
0.8 |
— |
— |
— |
1 |
1 |
(1) |
||||||||||||||
|
Health Care |
(0.9) |
— |
— |
— |
— |
— |
(1) |
||||||||||||||
|
(a) |
Lost volume related to the European strategic changes and pulp and tissue restructuring actions. |
|
(b) |
Mix/Other includes rounding. |
|
Unaudited | |
|
| ||||||||||
|
OUTLOOK FOR 2013 | ||||||||||
|
ESTIMATED FULL YEAR 2013 DILUTED EARNINGS PER SHARE | ||||||||||
|
Adjusted earnings per share |
$ |
5.65 |
- |
$ |
5.75 |
|||||
|
Adjustments for: |
||||||||||
|
European strategic changes |
(0.18) |
- |
(0.15) |
|||||||
|
Devaluation of Venezuelan bolivar |
(0.07) |
- |
(0.07) |
|||||||
|
Per share basis — diluted net income attributable to |
$ |
5.40 |
- |
$ |
5.53 |
|||||
|
ESTIMATED FULL YEAR 2013 EFFECTIVE TAX RATE | ||||||||||
|
Adjusted effective tax rate |
30.0 |
% |
- |
32.0 |
% | |||||
|
Adjustments for: |
||||||||||
|
European strategic changes |
1.0 |
- |
1.0 |
|||||||
|
Devaluation of Venezuelan bolivar |
— |
- |
— |
|||||||
|
Effective tax rate |
31.0 |
% |
- |
33.0 |
% | |||||
(Logo: http://photos.prnewswire.com/prnh/20110928/DA76879LOGO)
[KMB-F]
SOURCE
News Provided by Acquire Media